Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hydronidone Mass Balance Study in Chinese Healthy Adult Male Participants
NCT07471217Phase 1Completed
- Sponsor
- Gyre Pharmaceuticals
- Start
- Apr 2026
- Primary completion
- May 2026
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of hydronidone in Liver Fibrosis (LF), sponsored by Gyre Pharmaceuticals. Primary endpoints: Cumulative radioactive recovery in excreta (urine and feces) per collection period, Cumulative total radioactive recovery in excreta (urine and feces) and 13 more. Started Apr 2026; status: completed.
02
Drugs
hydronidone
03
Conditions
Liver Fibrosis (LF)
Beyond the preview
Go deeper on NCT07471217.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07471217.